Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research
Activity Outline
Opioid Overdose Response and Naloxone Training
July 25, 2024
Zoom.gov

Activity Coordinators:
Nina Mezu-Nwaba (nina.nwaba@fda.hhs.gov),  Sasha Latonis (Sasha.Latonis@fda.hhs.gov),  Surjit Basi (Surjit.Basi@fda.hhs.gov)
Description

This training is a 90-minute session which includes both didactic and practical skills training for participants focused on the recognition and response to respiratory arrest related to an opioid crisis, and the intervention using naloxone. Naloxone kits will not be distributed at this training.

Naloxone is a prescription medication that reverses an opioid overdose by restoring breathing and has minimal side effects. Take advantage of this opportunity to learn how to administer naloxone and learn what to do until help arrives.

References
  • Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health 2003;80:291–301
  • Centers for Disease Control and Prevention Unintentional poisoning deaths—United States, 1999–2004. MMWR Morb Mortal Wkly
  • Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction 2001;96:1113–1125
  • Powis B, Strang J, Griffiths P, et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction 1999;94:471–478
  • Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six naloxone training and distribution programs in the United States. Addiction 2008;103:979–989
  • Kim D, Irwin KS, Khoshnood K. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality
Learning Objectives
  • Discuss the various forms of naloxone administration and demonstrate naloxone administration.
  • Explain legal protections and reporting requirements following naloxone administration.
  • Describe further resuscitation activities following naloxone administration.
  • Explain the importance of calling 9-1-1.
  • Describe the steps in responding to an opioid overdose victim.
  • Describe the indications for and effects of naloxone.
  • Recognize the signs and symptoms of an Opioid Overdose.
  • Assess the likelihood of an opioid overdose in a simulated overdose victim.
Target Audience
This activity is intended for physicians, pharmacists, and nurses.
Registration Information
Registration is complimentary; therefore refunds are not applicable. For information on how to register to attend this activity, please contact the Activity Coordinator(s) listed above.
Agenda
Day 1 July 25, 2024
Time Topic Speaker
10:00 - 10:05 AM EDT Overview Nina Mezu-Nwaba, PharmD, MPH, MSc
10:05 - 11:15 AM EDT Opioid Overdose and Naloxone Training Session Sadaf Nabavian, PharmD
Chiemena Anyanwu, RN
11:15 - 11:25 AM EDT Skills / Training Exercise Sadaf Nabavian, PharmD
Chiemena Anyanwu, RN
11:25 - 11:30 AM EDT Conclusion / Wrap-up Nina Mezu-Nwaba, PharmD, MPH, MSc
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-24-079-L08-P for 1.50 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.50 contact hour(s).
Requirements for Receiving CE Credit

All learners claiming credit must attest to their attendance and complete all required activity evaluation(s) in the FDA CE Portal (ceportal.fda.gov) within 14 days after an activity ends. Upon completion, learners may view/print statement of credit.

Attention NABP Pharmacists and Pharmacy Technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy (NABP) provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor. If you do not see your credit reflected on CPE Monitor* after 45 days of attestation, please contact FDACETeam@fda.hhs.gov. *CPE Monitor sets a strict 60-day limit on uploading credits.

Disclosure

Faculty
  • Anyanwu, Chiemena, RN, International Policy analyst, FDA - nothing to disclose
  • Mezu-Nwaba, Nina, PharmD, MPH, MSc, Deputy Office Director, Office of Neurological and Physical Medicine Devices, HHS/FDA/CDRH - nothing to disclose
  • Nabavian, Sadaf, PharmD, Senior Regulatory Project Manager, FDA - nothing to disclose

Planning Committee
  • Mezu-Nwaba, Nina, PharmD, MPH, MSc, Deputy Office Director, Office of Neurological and Physical Medicine Devices, HHS/FDA/CDRH - nothing to disclose
  • Mezu-Patel, Ngozi, MD, Clinical Director, United States Public Health Service - nothing to disclose
  • Zellner, Renee, RN, MPH, BSN, Regulatory Project Manager, CDER - nothing to disclose

CE Consultation and Accreditation Team
  • Faberlle, Alexandra M., Training Specialist / FDA/CDER/OEP/DLOD - nothing to disclose
  • Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose
Any relationship shown above in italics has been divested within the last 24 months and is therefore considered mitigated.
All relevant financial relationships have been mitigated.
Requirements for Certificate of Completion (Non CE)
Must attend 100% of the activity.